A Questionnaire-based Survey to Understand the Role of Ceftazidime-avibactam in the Management of Carbapenem-Resistant Infections in Indian ICU Settings
Abstract
Introduction Antimicrobial resistance is serious and growing threat, with the increasing prevalence of MDR gram-negative bacteria worldwide, especially carbapenem-resistant Enterobacteriaceae (CRE). Ceftazidime-avibactam (CAZ-AVI) is a targeted first-line, and ICMR guideline recommended treatment option against CRE. Objectives To understand the role of CEF-AVI in the management of carbapenem-resistant infections among specialists in India. Materials and methods A questionnaire-based survey involving infectious disease specialists and intensivists was conducted in India. A digital questionnaire comprising 17 questions assessed the perception of CEF-AVI use in CRE infections among the survey participants. Data from completed questionnaires were retrieved and analyzed. Results A total of 102 participants completed the survey. Participants reported a 20–40% prevalence of carbapenem-resistant E. coli (40.20%), K. pneumoniae (46.08%), P. aeruginosa (46.08%), and Acinetobacter (49.02%) respectively, in their intensive care unit settings. More than half of the participants prescribed CEF-AVI either alone or in combination for HAP/VAP (52.94%) and 22.55% preferred in all approved indications (cUTI/cIAI/HAP/VAP/BSI). While in CRE suspected patients, 31.37% participants preferred CEF-AVI in combination with aztreonam as empirical therapy for complicated urinary tract infections, 35.29% preferred in hospital-acquired pneumonia/ventilator-associated pneumonia (HAP/VAP) and 42.16%…
Read the paper
Related studies
- Penicillins for Treatment of Pneumococcal Pneumonia: Does In Vitro Resistance Really Matter?
- Thiophenes—Naturally Occurring Plant Metabolites: Biological Activities and In Silico Evaluation of Their Potential as Cathepsin D Inhibitors
- Inhalable Mannosylated Rifampicin–Curcumin Co-Loaded Nanomicelles with Enhanced In Vitro Antimicrobial Efficacy for an Optimized Pulmonary Tuberculosis Therapy
- Development and validation of microbial bioassay for quantification of Levofloxacin in pharmaceutical preparations
- GC-MS Analysis and Biomedical Therapy of Oil from n-Hexane Fraction of Scutellaria edelbergii Rech. f.: In Vitro, In Vivo, and In Silico Approach
- Propranolol, chlorpromazine and diclofenac restore susceptibility of extensively drug-resistant (XDR)-Acinetobacter baumannii to fluoroquinolones
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.